In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) closed the day trading at $5.63 down -2.60% from the previous closing price of $5.78. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 0.55 million shares were traded. FDMT stock price reached its highest trading level at $5.94 during the session, while it also had its lowest trading level at $5.5.
Ratios:
For a better understanding of FDMT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.36 and its Current Ratio is at 12.36. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on January 13, 2025, Downgraded its rating to Market Perform and sets its target price to $15 from $40 previously.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 16 ’24 when Bizily Scott sold 500 shares for $16.33 per share. The transaction valued at 8,165 led to the insider holds 6,781 shares of the business.
Bizily Scott sold 500 shares of FDMT for $7,500 on Aug 19 ’24. The Chief Legal Officer now owns 6,781 shares after completing the transaction at $15.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 260807504 and an Enterprise Value of -36776264. For the stock, the TTM Price-to-Sale (P/S) ratio is 13040.50 while its Price-to-Book (P/B) ratio in mrq is 0.56. Its current Enterprise Value per Revenue stands at -1598.968 whereas that against EBITDA is 0.185.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.81, which has changed by -0.6246667 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $17.41, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 27.69%, while the 200-Day Moving Average is calculated to be 12.21%.
Shares Statistics:
Over the past 3-months, FDMT traded about 1.04M shares per day on average, while over the past 10 days, FDMT traded about 4249260 shares per day. A total of 46.32M shares are outstanding, with a floating share count of 41.55M. Insiders hold about 10.31% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for FDMT as of 1752537600 were 3619133 with a Short Ratio of 3.49, compared to 1749772800 on 4171819. Therefore, it implies a Short% of Shares Outstanding of 3619133 and a Short% of Float of 8.129999999999999.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$0.95, with high estimates of -$0.79 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.07 and -$4.06 for the fiscal current year, implying an average EPS of -$3.56. EPS for the following year is -$3.84, with 9.0 analysts recommending between -$2.8 and -$5.14.
